This updated analysis from the ShortHER trial provides, to our knowledge, the first evidence of an independent effect of TILs on OS in patients with ERBB2-positive early breast cancer treated with adjuvant chemotherapy and trastuzumab. This evidence concerns the gene ERBB2 and breast carcinoma.